Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Weekly Snapshot

PharmaShots Weekly Snapshots (Apr 12 – 16, 2021)

ThermoFisher to Acquire PPD for ~$17.4B Published: Apr 16, 2021 | Tags: ThermoFisher, Acquire, PPD, ~$17.4B Roche’s Evrysdi (risdiplam) Receives Health Canada’s Approval for Spinal Muscular Atrophy in Adults and Children Published: Apr 16, 2021 | Tags: Roche, Evrysdi (risdiplam), Receives, Health Canada, Approval, Spinal Muscular Atrophy, Adults, Children GSK Discontinues the P-II Trials of […]Read More

M&A MedTech

ThermoFisher to Acquire PPD for ~$17.4B

Shots: ThermoFisher to acquire PPD for $47.50/share making a total purchase price of $17.4B along with ~$3.5B of net debt with a premium of ~24% to the closing price of PPD’s common stock as of Apr 13, 2021. The transaction is expected to be completed by the end of 2021 The acquisition expands ThermoFisher’s service […]Read More

Clinical Trials

GSK Discontinues the P-II Trials of Feladilimab for Advanced or

Shots: GSK has stopped the enrollment in its P-II INDUCE-3 trial, including discontinuing treatment with feladilimab, following the recommendation by IDMC The P-II INDUCE-3 study involves assessing feladilimab + Merck’s pembrolizumab vs PBO+ pembrolizumab in patients with PD-L1+ recurrent LA/m-HNSCC. Additionally, GSK has also stopped the P-II INDUCE-4 study that evaluates feladilimab vs PBO in […]Read More


Prestige Biopharma and Pharmapark Sign an Exclusive License and Supply

Shots: Pharmapark to get exclusive rights to commercialize HD204 and is responsible for local registration, sales, and marketing of the biosimilar in Russia in collaboration with Russian import substitution strategy Prestige BioPharma will be responsible for commercial supply the product out of its manufacturing facilities in Osong, Korea Prestige’s (HD204) is currently being evaluated in […]Read More


Insights+: The US FDA New Drug Approvals in March 2021

The US FDA has approved 7 NDAs in Mar 2021, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 19 novel products in 2021. Additionally, last year in 2020, the US FDA has approved […]Read More


Boehringer Ingelheim and MD Anderson Expand their Collaboration to Accelerate

Shots: Boehringer Ingelheim and MD Anderson expand their 2019 joint VRDC to explore new molecules from Boehringer Ingelheim’s KRAS and TRAILR2 portfolios for lung cancer, particularly NSCLC The joint research will continue for 5 additional years. The extended collaboration follows successful preclinical studies in GI cancers via joint VRDC The expanded agreement allows the partners […]Read More